Thermo Fisher Scientific has chosen the Institute of Medical Genetics and Pathology at Switzerland's University Hospital Basel as a partner for a centre of excellence scheme.
The Basel site has been selected as the first partner within the company's Next Generation Sequencing Companion Dx Center of Excellence programme, an initiative designed to develop and refine the company's next-generation sequencing-based research assays.
“Thermo Fisher Scientific has selected the Institute of Medical Genetics and Pathology at Switzerland's University Hospital Basel as a centre of excellence partner.“
Drawing upon Thermo Fisher Scientific's Oncomine oncology portfolio, the aim of this research will be to eventually introduce the assays into the clinic as companion diagnostics to aid personalised treatment of various cancers.
Both organisations will work together to form global alliances and strategic partnerships with biopharmaceutical groups and others, with the institute itself carrying out research and validation of the Oncomine portfolio of products.
Mark Stevenson, president of life science solutions for Thermo Fisher Scientific, said: "We are committed to being the industry's partner of choice in this effort and Thermo Fisher will continue to forge new strategic alliances with leading global organisations that share our vision of a healthier world."
With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Science